1. Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
- Author
-
Rong Shi, Leonid Gibiansky, Chunze Li, Jin Yan Jin, Colby S. Shemesh, Pascal Chanu, Tong Lu, Jamie Hirata, Dan Lu, Uzor Ogbu, Sandhya Girish, Dale Miles, Priya Agarwal, and Randall C. Dere
- Subjects
Male ,Oncology ,Immunoconjugates ,Pharmaceutical Science ,030226 pharmacology & pharmacy ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,population pharmacokinetics ,Obinutuzumab ,Medicine ,Drug Dosage Calculations ,Pharmacology (medical) ,Aged, 80 and over ,Clinical Trials as Topic ,education.field_of_study ,non-Hodgkin lymphoma ,Lymphoma, Non-Hodgkin ,Age Factors ,Antibodies, Monoclonal ,Middle Aged ,integrated two-analyte ,Polatuzumab vedotin ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,Rituximab ,Research Paper ,Biotechnology ,medicine.drug ,Adult ,Bendamustine ,medicine.medical_specialty ,Population ,Models, Biological ,antibody-drug conjugate ,Young Adult ,03 medical and health sciences ,Sex Factors ,Pharmacokinetics ,Internal medicine ,Humans ,Computer Simulation ,Clinical significance ,Dosing ,education ,Aged ,Pharmacology ,business.industry ,Body Weight ,Organic Chemistry ,chemistry ,business - Abstract
Purpose The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. Methods Model simulations based on individual empirical Bayes estimates were used to evaluate the impact of intrinsic/extrinsic factors as patient subgroups on Cycle 6 exposures. Intrinsic factors included bodyweight, age, sex, hepatic and renal functions. Extrinsic factors included rituximab/obinutuzumab or bendamustine combination with pola and manufacturing process. The predicted impact on exposures along with the established exposure-response relationships were used to assess clinical relevance. Results No clinically meaningful differences in Cycle 6 pola exposures were found for the following subgroups: bodyweight 100–146 kg versus 38–versus versus male, mild hepatic impairment versus normal, mild-to-moderate renal impairment versus normal. Co-administration of rituximab/obinutuzumab or bendamustine, and change in the pola manufacturing process, also had no meaningful impact on PK. Conclusions In patients with NHL, bodyweight-based dosing is adequate, and no further dose adjustment is recommended for the heavier subgroup (100–146 kg). In addition, no dose adjustments are recommended for other subgroups based on intrinsic/extrinsic factors evaluated.
- Published
- 2020